Your Location：Home > Products > Pharmaceutical > Linagliptin

Linagliptin

Basic information

  • Product Name:Linagliptin
  • CasNo.:668270-12-0
  • Molecular Formula:C25H28N8O2
  • Molecular Weight:

Physical and Chemical Properties

  • Purity:99%
  • Boiling Point:
  • Packing:
  • Throughput:
Inquiry

Product Details

CasNo： 668270-12-0

Molecular Formula： C25H28N8O2

Factory Supply High Purity Linagliptin 668270-12-0 In Bulk Supply

668270-12-0 Name

Name

Linagliptin

Synonym

 linagliptin;8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione;(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione;1H-Purine-2,6-dione, 8-((3R)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-;Bi 1356;Ondero;8-[(3R)-3-AMino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-Methyl-1-[(4-Methyl-2-quinazolinyl)Methyl]-1H-purine-2,6-dione;8-[(3R)-3-AMino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-Methyl-1-[(4-Methyl-2-quinazolinyl)Methyl]-1H-purine-2,6-d

 

668270-12-0 Biological Activity

Related Catalog

Signaling Pathways >> Metabolic Enzyme/Protease >> Dipeptidyl Peptidase

Research Areas >> Metabolic Disease

Target

IC50: 1 nM (DPP-4)

High Purity Linagliptin 668270-12-0 Usage

Linagliptin (LNG) is a potent DPP- IV inhibitor, shows favorable anti-inflammatory effects in several animal model pathologies. LNG is a novel hypoglycemic drug. Linagliptin administered during morphine withdrawal significantly reduced the depressive behavior in studied mice. Linagliptin belongs to a group of new antihyperglycaemic drugs which have long half-time (T0.5 = 12 h) and linagliptin, as a selective DPP-4 inhibitor, indirectly increases the level of endogenous GLP-1 peptide. 

InChI:InChI=1/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1

668270-12-0 Relevant articles

Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial

Julio Rosenstock MD, Ahmed A. Kolkailah MD, Darren K. McGuire MD, Mark A. Espeland PhD, Michaela Mattheus MSc, Egon Pfarr MSc, Søren S. Lund MD, Nikolaus Marx MD, on behalf of the CAROLINA Investigators

Diabetes, Obesity and Metabolism Volume25, Issue6 June 2023 Pages 1453-1463

Dipeptidyl peptidase-4 (DPP-4) inhibitors such as linagliptin are antihyperglycaemic agents with a well-established efficacy and safety profile, a low risk of hypoglycaemia and body-weight neutrality. Across the severity spectrum, linagliptin substantially reduced the hypoglycaemic burden versus glimepiride in patients with relatively early type 2 diabetes at increased cardiovascular risk.

Linagliptin drug molecule as corrosion inhibitor for mild steel in 1 M HCl solution: Electrochemical, SEM/XPS, DFT and MC/MD simulation approach

Nkem B. Iroha a, Valentine Chikaodili Anadebe , Ngozi J. Maduelosi , Lebe A. Nnanna , Lucky Cole Isaiah , Omar Dagdag , Avni Berisha , Eno E. Ebenso 

Colloids and Surfaces A: Physicochemical and Engineering Aspects Volume 660, 5 March 2023, 130885

Linagliptin (LGP) was investigated as a mild steel (MS) corrosion inhibitor in 1 M HCl solution using combined experimental and theoretical explorations. The current study is focused on the ability of Linagliptin to inhibit mild steel dissolution in 1 M HCl solution. Linagliptin is a medication mainly used together with diet and exercises in type 2 diabetes management.

668270-12-0 Process route

(R)-7-(but-2-yn-1-yl)-8-(3-(1,3-dioxoisoindolin-2-yl)piperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine2,6-dione
886588-63-2

(R)-7-(but-2-yn-1-yl)-8-(3-(1,3-dioxoisoindolin-2-yl)piperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine2,6-dione

ethanolamine
141-43-5

ethanolamine

Linagliptin
668270-12-0

Linagliptin

(R)-N<SUP>1</SUP>-(1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)-N<SUP>2</SUP>-(2-hydroxyethyl)phthalamide

(R)-N1-(1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)-N2-(2-hydroxyethyl)phthalamide

(R)-2-((1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamoyl)benzoic acid

(R)-2-((1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamoyl)benzoic acid

N,N'-bis((R)-1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)phthalamide

N,N'-bis((R)-1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)phthalamide

Conditions
Conditions Yield
With water; In tetrahydrofuran; at 60 ℃; for 3h;
81.9%
1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert-butoxycarbonylamino)-piperidin-1-yl]-2,6-dioxo-2,3,6,7-tetrahydro-1H-purine

1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert-butoxycarbonylamino)-piperidin-1-yl]-2,6-dioxo-2,3,6,7-tetrahydro-1H-purine

Linagliptin
668270-12-0

Linagliptin

Conditions
Conditions Yield
1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert-butoxycarbonylamino)-piperidin-1-yl]-2,6-dioxo-2,3,6,7-tetrahydro-1H-purine; With hydrogenchloride; In dichloromethane; water; at 20 ℃; for 3h;
With hydrogenchloride; In ethanol; water; at 35 ℃; for 2h; Temperature;
99.2%
With methanol; water; Reflux; Inert atmosphere;
96.8%
With methanol; water; Inert atmosphere; Reflux;
96.8%
With methanol; water; Temperature; Reagent/catalyst; Inert atmosphere; Reflux;
92.8%
With methanol; water; Reagent/catalyst; Reflux; Inert atmosphere;
92.8%
With trifluoroacetic acid; In dichloromethane; at 20 ℃; for 1h;
91%
With trifluoroacetic acid; In dichloromethane; at 5 - 20 ℃; for 5h;
91%
With trifluoroacetic acid; In dichloromethane; at 0 - 30 ℃; for 12h;
90%
1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert-butoxycarbonylamino)-piperidin-1-yl]-2,6-dioxo-2,3,6,7-tetrahydro-1H-purine; With trifluoroacetic acid; In dichloromethane; at 20 ℃; Inert atmosphere;
With water; In 1,2-dichloro-ethane;
88%
With trifluoroacetic acid; In dichloromethane; at 10 - 20 ℃; for 5h; Concentration; Reagent/catalyst; Solvent;
87.2%
With formic acid; trifluoroacetic acid; at 10 - 20 ℃;
87.3%
With trifluoroacetic acid; In dichloromethane; at 10 ℃; for 3h;
87.21%
With trifluoroacetic acid; In dichloromethane; at 5 - 25 ℃; for 4h; Large scale;
82%
With trifluoroacetic acid; In dichloromethane; at 1 - 15 ℃; for 20h;
79%
1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert-butoxycarbonylamino)-piperidin-1-yl]-2,6-dioxo-2,3,6,7-tetrahydro-1H-purine; With hydrogenchloride; In methanol; water; for 4h; Reflux;
With sodium hydroxide; In methanol; water; for 5h; Reflux;
70%
With trifluoroacetic acid; In dichloromethane; at 0 - 25 ℃; for 24h; Inert atmosphere;
44%
With trifluoroacetic acid; In dichloromethane; water; at 20 ℃; for 3h; pH=8; Solvent; Reagent/catalyst; Temperature; Time;
69 g
With trifluoroacetic acid; In dichloromethane; at 25 ℃; for 2h;
 
With trifluoroacetic acid; In dichloromethane; at 25 - 40 ℃;
 
With trifluoroacetic acid; In dichloromethane; at 20 ℃; for 3h;
2.8 g
With trifluoroacetic acid; In dichloromethane; at 15 - 30 ℃; for 3h;
23 g
With trifluoroacetic acid; In dichloromethane; for 2h;
 
With trifluoroacetic acid; In dichloromethane; at 20 ℃; for 1.5h; Concentration;
 
With trifluoroacetic acid; In dichloromethane; at 20 - 25 ℃;
 
With hydrogenchloride; In methanol; dichloromethane; at 45 ℃; for 4h;
4.99g
With trifluoroacetic acid; In dichloromethane; at 40 - 45 ℃;
 
With zinc(II) chloride; In dichloromethane; at 30 ℃; for 5h; Temperature; Reagent/catalyst; Solvent;
68.6 g
With trifluoroacetic acid; In dichloromethane; at 25 ℃; for 2h; Temperature; Large scale;
3.4 kg
With trifluoroacetic acid; at 30 - 40 ℃; for 3h;
153.5 g

668270-12-0 Upstream products

  • 886588-63-2
    886588-63-2

    (R)-7-(but-2-yn-1-yl)-8-(3-(1,3-dioxoisoindolin-2-yl)piperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine2,6-dione

  • 163343-71-3
    163343-71-3

    (R)-piperidine-3-carboxylic acid ethyl ester*l-tartaric acid

  • 853029-57-9
    853029-57-9

    2-bromo-1-(but-2-ynyl)-4-methyl-6-((4-methylquinazolin-2-yl)methyl)-1H-imidazo[4,5-b]pyridine-5,7-(4H,6H)-dione

  • 334618-23-4
    334618-23-4

    3-(R)-aminopiperidine dihydrochloride

Relevant Products